Everolimus for cardiac allograft vasculopathy-every patient, at any time?

Transplantation

Volumn 92, Issue 2, 2011, Pages 127-128

  Patel, Jignesh K ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; HEART TRANSPLANTATION; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AZATHIOPRINE; CALCINEURIN; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MUSCLE, SMOOTH, VASCULAR; MYCOPHENOLIC ACID; RISK FACTORS; SIROLIMUS; VASCULAR DISEASES;

EID: 79960321107     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318220588f     Document Type: Note

References (6)

1. Arora S, Ueland T,Wennerblom B, et al. Effectofeverolimusintroduc-tion on cardiac allograft vasculopathy\-results ofarandomized, mul-ticenter trial. Transplantation 2011; 92: 235.
2. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694.
3. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. NEngl JMed 2003; 349: 847.
4. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound (IVUS) validation study among heart transplant recipients: Outcomes after 5 years. JAm Coll Cardio 2005; 45: 1532.
5. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows pro-gression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48.
6. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with my-cophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377.